19-Nor-1α, 25-dihydroxyvitamin D2 (paricalcitol): Effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines

Journal of Cancer Research and Clinical Oncology

Volumn 129, Issue 1, 2003, Pages 35-42

  Molnár, István ^a   Kute, Timothy ^a   Willingham, Mark C ^a   Powell, Bayard L ^a   Dodge, William H ^a   Schwartz, Gary G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Differentiation; Experimental therapeutics; HL 60; Paricalcitol; U937

Indexed keywords

CALCITRIOL; CD11B ANTIGEN; CD14 ANTIGEN; LIPOCORTIN 5; NITROBLUE TETRAZOLIUM; PARATHYROID HORMONE; PARICALCITOL; PROPIDIUM IODIDE; ANTINEOPLASTIC AGENT; ERGOCALCIFEROL;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN U937; CHRONIC KIDNEY FAILURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; CANCER STEM CELL; CELL CYCLE; CELL DIVISION; DOSE RESPONSE; DRUG SCREENING; LEUKEMIA; MOLECULAR CLONING; TIME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CLONING, MOLECULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOCALCIFEROLS; HL-60 CELLS; HUMANS; LEUKEMIA; TIME FACTORS; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS; U937 CELLS;

EID: 0038777279     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-002-0405-7     Document Type: Article

References (44)

1. 3. Proc Natl Acad Sci U S A 78:4990-4995
2. Albanell J, Han W, Mellado B, Gunawardane R, Scher HI, Dmitrovsky E, Moore MA (1996) Telomerase activity is repressed during differentiation of maturation- sensitive but not resistant human tumor cell lines. Cancer Res 56:1503-1508
3. Arlet P, Nicodeme R, Adoue D, Larregain-Fournier D, Delsol G, le Tallec Y (1984) Clinical evidence for 1,25-hydroxycholecalciferol action in myelofibrosis. Lancet 1:1013-1014
4. Asou H, Koike M, Elstner E, Cambell M, Le J, Uskokovic M, Kamada N, Koeffler HP (1998) 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 92:2441-2449
5. 3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138:1491-1497
6. 2 as therapeutic agents for prostate cancer. Clin Cancer Res 6:901-908
7. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD (1998) Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 392:505-509
8. 3 analogue (KH 1060) with 9-cis- retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 56:3570-3576
9. 3. Cell Prolif 27:37-46
10. 3, that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood 97:2427-2433
11. 2, a vitamin D analog with reduced bone resorbing activity in vitro. J Am Soc Nephrol 11:1857-1864
12. James SY, Turner A, Colston KW (1997a) Induction of apoptosis in human leukemia cells is differently regulated by vitamin D derivatives and retinoids. Hematology 2:289-301
13. James SY, Williams MA, Kelsey SM, Newland AC, Colston KW (1997b) The role of vitamin D derivatives and retinoids in the differentiation of human leukaemia cells. Biochem Pharmacol 54:625-634
14. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB (1994) Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9:3397-3406
15. 3 on the proliferation of pancreatic cancer cell lines. Gastroenterology 110:1605-1613
16. 3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 69:1399-1407
17. 3 analog, EB1089, on hematopoietic stem cells from normal and myeloid leukemic blasts. Leukemia 10:1751-1757
18. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153
19. 2. Am J Kidney Dis 32:S61-S66
20. Mayfield S, Vaughn JP, Kute TE (2001) DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines. Breast Cancer Res Treat 70:123-129
21. 3 inhibits proliferation of human promyelocytic leukemia (HL-60) cells and induces monocyte-macrophage differentiation in HL-60 and normal bone marrow cells. Leuk Res 7:51-55
22. Mehta AB, Kumaran TO, Marsh GW, McCarthy DM (1984) Treatment of advanced myelodysplastic syndrome with alfacalcidol. Lancet 2:761
23. Mellibovsky L, Diez A, Perez-Vila E, Serrano S, Nacher M, Aubia J, Supervia A, Recker RR (1998) Vitamin D treatment in myelodysplastic syndromes. Br J Haematol 100:516-520
24. 3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 38:67-68
25. Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W, Andreeff M, Koeffler HP (1996) A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 88:2201-2209
26. Nagy L, Thomazy VA, Shipley GL, Fesus L, Lamph W, Heyman RA, Chandraratna RAS, Davis PJA (1995) Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 15:3540-3551
27. Newburger PE, Chovaniec ME, Greenberger JS, Cohen HJ (1979) Functional changes in human leukemic cell line HL-60. A model for myeloid differentiation. J Cell Biol 82:315-322
28. Pakkala I, Savli H, Knuutila S, Binderup L, Pakkala S (1997) CB1093, a novel vitamin D analog; effects on differentiation and clonal growth on HL-60 and de novo leukemia cells. Leuk Res 21:321-326
29. 3 analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27. Exp Cell Res 254:279-286
30. 3. Am J Hematol 23:175-178
31. 1 that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood 93:2721-2729
32. 3 in cultured human epidermal keratinocytes. J Invest Dermatol 109:46-54
33. 1 cell cycle regulatory proteins in HL-60 cells. Int J Oncol 16:315-320
34. 3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 42:31-41
35. Slapak CA, Desforges JF, Fogaren T, Miller KB (1992) Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am J Hematol 41:178-183
36. 2D2): a new vitamin D drug for renal osteodystrophy. In: Norman AW, Bouillon R, Thomasset M (eds) Vitamin D: chemistry, biology and clinical applications of the steroid hormone: proceedings of the Tenth Workshop on Vitamin D, Strasbourg, 24-29 May 1997. Printing and Reprographics, Riverside, University of California
37. 3. Cancer Res 45:3898-3905
38. Studzinski GP, Rathod B, Wang QM, Rao J, Zhang F (1997) Uncoupling of cell cycle arrest from the expression of monocytic differentiation markers in HL60 cell variants. Exp Cell Res 232:376-387
39. 3 in HL60 cells. Cancer Res 56:264-267
40. 3 receptor. Blood 98:3290-3300
41. Willingham MC (1999) Cytochemical methods for the detection of apoptosis. J Histochem Cytochem 47:1101-1109
42. 3 and its analogue, EB1089, in human breast cancer cells. Oncogene 15:1555-1563
43. 0 phase cell cycle block. Cell Prolif 27:643-654
44. Zhou J-Y, Norman AW, Lubbert M, Collins ED, Uskokovic MR, Koeffler HP (1989) Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone calcium mobilization. Blood 74:82-93